

Contents

Preface XIX

List of Contributors XXIII

1	The Amyloid Phenomenon and Its Significance	1
	<i>Christopher M. Dobson</i>	
1.1	Introduction	1
1.2	The Nature of the Amyloid State of Proteins	1
1.3	The Structure and Properties of Amyloid Species	5
1.4	The Kinetics and Mechanism of Amyloid Formation	7
1.5	The Link between Amyloid Formation and Disease	9
1.6	Strategies for Therapeutic Intervention	11
1.7	Looking to the Future	14
1.8	Summary	15
	Acknowledgments	16
	References	16
2	Amyloid Structures at the Atomic Level: Insights from Crystallography	21
	<i>Michael R. Sawaya and David Eisenberg</i>	
2.1	Atomic Structures of Segments of Amyloid-Forming Proteins	21
2.1.1	Protein Segments That Form Amyloid-Related Crystals	21
2.1.2	Atomic Structures of Fiber-Like Microcrystals	23
2.2	Stability of Amyloid Fibers	25
2.3	Which Proteins Enter the Amyloid State?	26
2.4	Molecular Basis of Amyloid Polymorphism and Prion Strains	27
2.5	Atomic Structures of Steric Zippers Suggest Models for Amyloid Fibers of Parent Proteins	28
2.6	Atomic Structures of Steric Zippers Offer Approaches for Chemical Interventions against Amyloid Formation	31
2.7	Summary	34
	Acknowledgments	36
	References	36

3	What Does Solid-State NMR Tell Us about Amyloid Structures?	39
	<i>Wolfgang Hoyer and Henrike Heise</i>	
3.1	Introduction	39
3.2	Principles of Solid-State NMR Spectroscopy and Experiments for Structural Constraints	40
3.2.1	Isotope Labeling, Magic Angle Spinning, Dipolar Coupling, and Resonance Assignment	40
3.2.2	Defining the Amyloid Core by Magnetization Transfer from Water	43
3.2.3	Determining the Fibril Registry	43
3.2.4	Seeded versus Unseeded Fibrils	44
3.3	Amyloid Fibrils Investigated by Solid-State NMR Spectroscopy	45
3.3.1	A β peptides of Different Length	46
3.3.2	Islet Amyloid Polypeptide (IAPP/Amylin): Parallel and Antiparallel Steric Zippers	47
3.3.3	α -Synuclein: Polymorphism with Flexible Terminal Regions	49
3.3.4	PrP: Rearrangements to Maintain a Fibrillar Core Region	51
3.3.5	Yeast Prions with Glutamine/Asparagine-Rich Prion Domains: Sup35p, Ure2p, and Rnq1p	52
3.3.6	Functional Amyloid: the Yeast Prion HET-s	52
3.4	Summary	53
	References	54
4	From Molecular to Supramolecular Amyloid Structures: Contributions from Fiber Diffraction and Electron Microscopy	63
	<i>Kyle L. Morris and Louise C. Serpell</i>	
4.1	Introduction	63
4.2	History	65
4.2.1	The Historical Use of X-ray Fiber Diffraction	65
4.2.2	The Historical Use of Transmission Electron Microscopy	67
4.3	Methodology	68
4.3.1	X-Ray Fiber Diffraction	68
4.3.2	Transmission Electron Microscopy	72
4.4	Recent Advances in Amyloid Structure Determination	73
4.4.1	X-ray Fiber Diffraction	73
4.4.2	Transmission Electron Microscopy	76
4.5	Summary	78
	Acknowledgments	79
	References	79
5	Structures of Aggregating Species by Small-Angle X-Ray Scattering	85
	<i>Cristiano L. P. Oliveira and Jan Skov Pedersen</i>	
5.1	Introduction	85
5.2	Theoretical and Experimental Aspects	85
5.3	Data Analysis and Modeling Methods	88

5.4	Studying Protein Aggregation and Fibrillation Using SAXS	91
5.4.1	Some General Considerations	91
5.4.2	SAXS Studies of Insulin, Glucagon, and α -Synuclein	92
5.4.3	SDS-Induced Aggregation of α -Synuclein	96
5.4.4	Multi-Component Fitting and Analysis of SAXS Data	97
5.5	General Strategies for Modeling SAXS Data from Protein Complexes	98
5.6	Summary and Final Remarks	100
	Acknowledgments	101
	References	101
6	Structural and Compositional Information about Pre-Amyloid Oligomers	103
	<i>Niels Zijlstra and Vinod Subramaniam</i>	
6.1	General Introduction	103
6.2	Biophysical Techniques to Study Amyloid Oligomers	104
6.2.1	Fluorescence Spectroscopy	104
6.2.1.1	Ensemble Spectroscopy	105
6.2.1.2	Single-Molecule Spectroscopy	105
6.2.2	Atomic Force Microscopy	107
6.2.3	Absorbance and Circular Dichroism Spectroscopy	108
6.2.4	Small-Angle X-Ray Scattering	108
6.2.5	Mass Spectrometry	109
6.3	The Structure and Composition of Amyloid Oligomers	109
6.3.1	α -Synuclein Oligomers	109
6.3.1.1	Morphology	110
6.3.1.2	Oligomer Structure	111
6.3.1.3	Oligomer Composition	113
6.3.2	A β Peptide Oligomers	115
6.3.2.1	Morphology	115
6.3.2.2	Composition	116
6.4	Concluding Remarks	116
	Acknowledgments	118
	References	118
7	The Oligomer Species: Mechanistics and Biochemistry	127
	<i>Massimo Stefani</i>	
7.1	Introduction	127
7.2	The Structure–Toxicity Relation of Early Amyloids	128
7.2.1	Antibodies Define Different Structural Classes of Oligomers and Fibrils	128
7.2.2	Proteins May Form Different Kinds of Oligomers with Different Structural and Biological Activities	129
7.3	The Oligomer–Membrane Complex	131
7.3.1	The Effect of Surfaces on Protein Misfolding and Aggregation	131

7.3.2	The Membrane Composition Affects Binding and Aggregation Processes	132
7.3.3	Complex Roles of Cholesterol and Gangliosides in Oligomer Cytotoxicity	133
7.4	Biochemical Modifications Underlying Amyloid Toxicity	134
7.4.1	A New View of the Amyloid Cascade Hypothesis	134
7.4.2	Amyloid Pores: a Mechanism for Cytotoxicity?	135
7.4.3	Other Mechanisms for Oligomer Cytotoxicity	137
7.4.3.1	Oxidative Stress and Amyloid Aggregates	138
7.4.3.2	Lipid Modification and Ca^{2+} Entry	139
7.4.3.3	The Complexity of Amyloid and Oligomer Polymorphism	140
7.5	Summary	141
	References	141
8	Pathways of Amyloid Formation	151
	<i>Francesco Bemporad and Fabrizio Chiti</i>	
8.1	Introduction	151
8.2	Nomenclature of the Various Conformational States	152
8.3	Graphical Representations of the Mechanisms Leading to Amyloid	153
8.3.1	Time Course of Amyloid Content	153
8.3.2	Energy Landscapes of Amyloid Fibril Formation	155
8.3.3	Reaction Equilibria Involved in Amyloid Fibril Formation	157
8.4	Pathways of Amyloid Fibril Formation	159
8.5	Nucleation Growth versus Nucleated Conformational Conversion	161
8.6	Summary	163
	References	163
9	Sequence-Based Prediction of Protein Behavior	167
	<i>Gian Gaetano Tartaglia and Michele Vendruscolo</i>	
9.1	Introduction	167
9.2	The Strategy of the Zyggregator Predictions	167
9.2.1	Prediction of the Effects of Amino Acid Substitutions on Protein Aggregation Rates	168
9.2.2	Prediction of the Overall Aggregation Rates of Peptides and Proteins	170
9.2.3	Prediction of Aggregation-Prone Regions in Amino Acid Sequences	171
9.3	Aggregation Under Other Conditions	173
9.3.1	Prediction of Protein Aggregation-Prone Regions in the Presence of Denaturants	173

9.3.2	Prediction of Aggregation-Prone Regions in Native States of Proteins	173
9.4	Prediction of the Cellular Toxicity of Protein Aggregates	174
9.5	Relationship to Other Methods of Predicting Protein Aggregation Propensities	175
9.6	Competition between Folding and Aggregation of Proteins	177
9.7	Prediction of Protein Solubility from the Competition between Folding and Aggregation	177
9.7.1	Sequence-Based Prediction of Protein Solubility	178
9.7.2	Prediction of the Solubility of Proteins Based on Their Cellular Abundance	178
9.8	Sequence-Based Prediction of Protein Interactions with Molecular Chaperones	179
9.9	Summary	179
	References	180
10	The Kinetics and Mechanisms of Amyloid Formation	183
	<i>Samuel I. A. Cohen, Michele Vendruscolo, Christopher M. Dobson, and Tuomas P. J. Knowles</i>	
10.1	Introduction	183
10.2	Classical Theory of Nucleated Polymerization	184
10.2.1	From Microscopic Processes to a Master Equation	184
10.2.2	Kinetic Equations for Experimental Observables	187
10.2.3	Characteristics of Oosawa-Type Growth	189
10.2.3.1	Nucleation and Growth Occur Simultaneously	189
10.2.3.2	The Early Stages of the Reaction Time Course Are Described by Polynomial Growth	189
10.2.3.3	The Late Stages of the Reaction Time Course are Described by Simple First-Order Kinetics	190
10.2.3.4	The Integrated Rate Laws Exhibit Scaling Behavior	191
10.2.4	Global Analysis of Experimental Data Using the Oosawa Theory	192
10.3	The Theory of Filamentous Growth with Secondary Pathways	193
10.3.1	Extending the Oosawa Framework to Include Fragmentation and Secondary Nucleation	193
10.3.2	Early Time Perturbative Solutions	195
10.3.3	Characteristics of Exponential-Type Growth	196
10.3.3.1	The Early Stages of the Reaction Time Course Are Exponential	196
10.3.3.2	The Solution Exhibits Scaling Behavior	198
10.3.4	Global Analysis of Experimental Data Using Linearized Solutions	198

10.4	Self-Consistent Solutions for the Complete Reaction Time Course	200
10.4.1	The Key Phenomenological Parameters Depend on Combinations of the Microscopic Rate Constants	202
10.4.2	Reaction Time Course with Depleted Monomer Concentration	202
10.4.3	Global Analysis of Amyloid Reaction Kinetics Using Self-Consistent Solutions	204
10.5	Summary	205
	References	205
11	Fluorescence Spectroscopy as a Tool to Characterize Amyloid Oligomers and Fibrils	211
	<i>Per Hammarström, Mikael Lindgren, and K. Peter R. Nilsson</i>	
11.1	Introduction	211
11.2	Fluorescence Spectroscopy for Studies of Amyloid Reactions <i>In vitro</i>	212
11.2.1	Fluorescence Output Formats	212
11.2.2	Fluorescence Anisotropy	212
11.2.3	Single Molecule Detection	214
11.2.4	Conformational Probes	214
11.3	Cysteine-Reactive Fluorescent Probes	214
11.3.1	Environmentally Sensitive Probes – Spectrochromic Stokes Shift Assay	214
11.3.2	Fluorescence Anisotropy Probes for Amyloid Oligomerization	216
11.3.3	Pyrene Excimer Formation Probes for amyloid Oligomer and Fibril Topology	217
11.3.4	Bifunctional Cysteine Reagents as Probes for Amyloid Oligomers and Fibrils	217
11.4	Amyloidotropic Probes for Amyloid Fibrils and Oligomeric States	218
11.4.1	Are There Selective Probes for Prefibrillar Oligomeric States?	223
11.4.2	Fluorescence Anisotropy of Small Molecule Probes for Capturing the Intermediate Oligomeric State	224
11.4.3	<i>In vivo</i> Fluorescent Probes for Amyloid Fibrils	225
11.5	Luminescent Conjugated Poly and Oligothiophenes LCPs and LCOs	228
11.5.1	Optical Properties of Chemically Defined LCOs	228
11.5.2	Bridging the Imaging and Spectroscopy Gap – Microspectroscopy of <i>In vivo</i> Formed Amyloids	230
11.5.3	Bridging the Imaging and Spectroscopy Gap: Microspectroscopy and Real Time Imaging of Amyloid Formation	232
11.5.4	New Nanoscopic and Multifunctional Fluorescence-Based Imaging Technologies	234

11.5.5	LCOs for Optical <i>In vivo</i> Imaging of Protein Aggregates in Transgenic Mouse Models	234
11.6	Summary	236
	Acknowledgments	237
	References	239
12	Animal Models of Amyloid Diseases	245
	<i>Stanislav Ott and Damian C. Crowther</i>	
12.1	Introduction	245
12.2	Some Big Questions Regarding Amyloid Diseases and Some Answers from Animal Models	247
12.3	Identifying the Toxic Species in the Systemic Amyloidoses	248
12.4	Identifying the Toxic Species in Alzheimer's Disease	250
12.5	Infectious Protein Misfolding	252
12.5.1	<i>Bona fide</i> Prion Disease	254
12.5.2	Prion-Like Diseases	254
12.6	Conclusions	256
	References	257
13	The Role of Aβ in Alzheimer's Disease	263
	<i>Timothy M. Ryan, Blaine R. Roberts, Victor A. Streltsov, Stewart D. Nuttall, and Colin L. Masters</i>	
13.1	History of Amyloidosis	263
13.1.1	Early Reports of Amyloidosis	263
13.1.2	Origins of Modern Definition of Amyloid	264
13.2	Biochemistry of A β	264
13.2.1	Identification of the Alzheimer's Amyloid Subunit	265
13.2.2	The Production and Processing of the A β Peptide	267
13.3	Amyloid Fibrils	268
13.3.1	Synthetic Structural Studies	268
13.3.2	<i>In vivo</i> Fibrillar Structure	269
13.4	The Soluble Oligomer Theory of AD	269
13.4.1	The Development of the Soluble Oligomer Theory of AD	269
13.4.2	Soluble Oligomers <i>In vivo</i>	270
13.4.3	Recombinant Soluble Oligomers	271
13.4.4	Synthetic A β Soluble Oligomers	271
13.5	Other Factors Involved in Amyloid Plaque Formation in AD	274
13.5.1	Interactions with Lipids and Membranes	275
13.5.2	Electrostatic Membrane Interactions	275
13.5.3	Integral Membrane Interactions	276
13.5.4	Other Lipid Interactions	277
13.5.5	Apolipoprotein Interactions	277
13.5.6	Receptor Interactions	277
13.6	Metal Ions in AD	278

13.6.1	Cu/A β Interactions	278
13.6.2	Zn/A β Interactions	279
13.6.3	Fe/A β Interactions	279
13.6.4	Other Metals Involved in AD	279
13.7	Other Potential A β Interactions	280
13.8	Other Neurodegenerative Diseases	280
13.9	Conclusion	280
	References	281
14	Experimental Approaches to Inducing Amyloid Aggregates	295
	<i>Lise Giehm and Daniel Otzen</i>	
14.1	The Need for Reproducible Fibrillation Assays	295
14.2	Setting Up an Assay to Monitor Fibrillation	296
14.3	Conditions That Promote Protein Aggregation	298
14.3.1	Formation of an Aggregation-Competent Amyloidogenic Precursor	303
14.3.2	Assembly of Aggregation-Prone Complexes via Additives Such as Surfactants or Lipids	308
14.3.3	Ability to Recruit Native-Like Monomers by an “Infectious” State	309
14.3.4	Minor Conformational Changes in an Essentially Native-Like Precursor	311
14.3.5	Promotion of Elongation and Nucleation Steps through Fragmentation	311
14.3.6	Miscellaneous Effects	312
14.4	Processing and Batch Differences	312
14.5	Toward High-Throughput Assays	313
14.6	Summary	314
	References	314
15	Fibrillar Polymorphism	321
	<i>Marcus Fändrich, Melanie Wulff, Jesper Søndergaard Pedersen, and Daniel Otzen</i>	
15.1	Detection of Fibrillar Polymorphism	321
15.2	The Structural Definition of Fibril Polymorphism	322
15.2.1	Inter-sample Polymorphism	322
15.2.2	Intra-Sample Polymorphism	326
15.2.3	Deformations from Ideal Helical Symmetry	326
15.3	The Two Classes of Fibril Polymorphism	328
15.3.1	Protofilament Assembly Polymorphisms: Different Orientations and Different Numbers of Protofilaments	328
15.3.1.1	Different Orientation	328
15.3.1.2	Different Numbers of Protofilaments	328
15.3.2	Protofilament Substructure Polymorphisms and Composite Fibril Structures	329

15.4	How Does Fibrillar Polymorphism Arise?	332
15.5	The Interconversion of Fibril Polymorphs	334
15.6	The Biological Implications of Fibril Polymorphism	335
15.7	Summary	337
	Acknowledgments	338
	References	338
16	Inhibitors of Amyloid and Oligomer Formation	345
	<i>Nikolai Lorenzen, Erich E. Wanker, and Daniel Otzen</i>	
16.1	Introduction: Amyloidoses versus Neurodegenerative Diseases	345
16.1.1	Antibody-Mediated Immunotherapy	346
16.1.1.1	Active Immunization	346
16.1.1.2	Passive Immunotherapy	348
16.1.1.3	The Blood Brain Barrier	349
16.1.2	Nucleic Acid-Based Agents against Protein Aggregates	349
16.1.3	Inhibition of Amyloid Formation by Small Molecules	350
16.1.3.1	Stabilizing the Native State	350
16.1.3.2	Structural Properties of Fibrillation Inhibitors	350
16.1.3.2.1	Unspecific Effects by Colloidal Agents	356
16.1.3.3	Polyphenols: a Potent Class of Amyloid Inhibitors	357
16.1.3.3.1	Epigallocatechin Gallate: the Universal Amyloid-Inhibitor?	357
16.1.3.4	Promoting Fibrillation to Avoid Toxic Oligomers	359
16.1.4	Peptides and Peptide Mimetics	360
16.1.5	Nanoparticles: Untamed Dragons with Fire Power to Heal?	361
16.2	Summary	362
	References	363
17	Development of Therapeutic Strategies for the Transthyretin Amyloidoses	373
	<i>Colleen Fearn, Stephen Connelly, Evan T. Powers, and Jeffery W. Kelly</i>	
17.1	Introduction to Transthyretin Structure and Function	373
17.2	Introduction to Amyloid Diseases in General	373
17.2.1	Transthyretin Amyloid Diseases	375
17.2.2	Current Strategies to Treat Human Amyloid Diseases	377
17.3	Mechanism of Transthyretin Amyloidogenesis	378
17.3.1	Kinetic Stabilization of the Transthyretin Tetramer Ameliorates Amyloid Disease – Genetic Evidence	379
17.4	Kinetic Stabilization of the Transthyretin Tetramer through Small-Molecule Binding	381
17.4.1	Bivalent Kinetic Stabilizers	384
17.4.2	Kinetic Stabilizers Must Bind Selectively to Transthyretin	385
17.5	Assessment of Diflunisal for Treatment of Transthyretin Amyloidosis	385
17.6	Tafamidis, the First Approved Drug for Treatment of a Transthyretin Amyloidosis	385

17.7	Summary	387
	References	387
18	Hormone Amyloids in Sickness and in Health	395
	<i>Carolin Seuring, Nadezhda Nespovitaya, Jonas Rutishauser, Martin Spiess, and Roland Riek</i>	
18.1	Introduction	395
18.2	Constitutive vs. Regulated Secretory Pathways	395
18.3	Secretory Granules Contain Aggregated Cargo	396
18.3.1	Secretory Protein Sorting and Granule Formation	396
18.3.2	Triggering the Formation of Secretory Granules	398
18.3.3	Triggering the Formation of Secretory Granules by Glycosaminoglycans (GAGs)	399
18.4	Secretory Granule Aggregation by Functional Amyloid Formation	401
18.5	Hormone Amyloids in Disease: Diabetes Insipidus	402
18.6	Conclusions	405
	References	405
19	Functional Amyloids in Bacteria	411
	<i>Morten S. Dueholm, Per Halkjaer Nielsen, Matthew Chapman, and Daniel Otzen</i>	
19.1	Introduction	411
19.2	Functional Amyloids are Common in Nature	412
19.3	Identification and Characterization of Functional Amyloids	413
19.4	Functional Bacterial Amyloids Play Many Roles	415
19.4.1	Biofilm Formation and Cell Clustering	415
19.4.2	Binding to Eukaryotic Cells	416
19.4.3	Oligomeric Toxins	417
19.4.4	Coating of Spores and other Cells	417
19.5	Biogenesis and Regulation of Functional Bacterial Amyloids	418
19.5.1	Curli	418
19.5.2	Functional Amyloids in <i>Pseudomonas</i>	418
19.5.3	Chaplins	420
19.5.4	Hydrophobins	420
19.6	Structural Composition of Functional Amyloids	421
19.6.1	Curli: Five Repeating Units and Essential Gln and Asn Residues	421
19.6.2	FapC Linkers of Variable Length: <i>Pseudomonas</i>	423
19.6.3	Chaplins: GN Motif and Conserved Cys Residues	423
19.6.4	Harpins: Small and Polar Residues	425
19.7	Assembly Properties of Functional Amyloid <i>In Vitro</i>	425
19.8	Diversity and Distribution of Functional Amyloid Genes	426
19.9	Summary	431
	Acknowledgments	433
	References	433

20	Structural Properties and Applications of Self-Assembling Peptides	439
	<i>Zhongli Luo and Shuguang Zhang</i>	
20.1	Introduction to Self-Assembling Peptides	439
20.2	The Principles of Self-Assembling Peptides	439
20.2.1	Design Principle for Self-Assembling Peptides	439
20.2.2	Conformational Changes Undergone by Self-Assembling Peptides	441
20.2.2.1	Effect of Temperature	441
20.2.2.2	Effect of pH	442
20.2.2.3	Effect of Amino Acid Sequence	442
20.3	Self-Assembling Peptide Nanofibers	443
20.3.1	The Nanofiber Structures of the Peptide Scaffold	443
20.3.2	The Process of Peptide Scaffold Formation	444
20.3.3	A Proposed Model for the Process of Nanofiber Formation	445
20.4	Diverse Applications of Self-Assembling Peptide Nanofibers Scaffolds	446
20.4.1	Three-Dimensional Tissue Cell Cultures	446
20.4.2	Cell and Tissue Engineering	448
20.4.3	Controlled Drug Delivery and Regenerative Medicine	450
20.4.4	Trauma Emergency	451
20.5	Summary	451
	Acknowledgments	452
	References	452
21	Harnessing the Self-Assembling Properties of Proteins in Spider Silk and Lung Surfactant	455
	<i>Jan Johansson</i>	
21.1	Introduction	455
21.2	Amino Acid Sequences and Amyloid Formation	455
21.3	Spider Silk and How the Spiders Make It	458
21.4	Harnessing the Properties of Spider Silk and Its Constituent Proteins	461
21.5	Biosynthesis of an α -Helix from One of the Most β -Prone Sequences Known	462
21.6	Anti-Amyloid Properties of the BRICHOS Domain	464
21.7	Summary	465
	Acknowledgments	465
	References	466
	Index	471